Gemini Therapeutics is creating novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Millions of people are affected by diseases like dry AMD, but the diseases are poorly defined, heterogeneous, and influenced by many genetic variants. By combining genetics and biology, Gemini is identifying genetic variants to define subpopulations of patients with AMD. From the subpopulations, Gemini can integrate clinical information to characterize the genetic variants linked with AMD and define their roles in disease pathogenesis. This analysis provides Gemini with information to develop precision medicines tailored to genetically defined subpopulations to improve clinical success.
Claim company profile to post jobs directly on this page and this website.